MX2021012743A - Compuestos de n-acil-{4-[(4-aril-fenil)sulfonilmetil]piperidina} y su uso terapeutico. - Google Patents

Compuestos de n-acil-{4-[(4-aril-fenil)sulfonilmetil]piperidina} y su uso terapeutico.

Info

Publication number
MX2021012743A
MX2021012743A MX2021012743A MX2021012743A MX2021012743A MX 2021012743 A MX2021012743 A MX 2021012743A MX 2021012743 A MX2021012743 A MX 2021012743A MX 2021012743 A MX2021012743 A MX 2021012743A MX 2021012743 A MX2021012743 A MX 2021012743A
Authority
MX
Mexico
Prior art keywords
compounds
present
sulfonylmethyl
piperidine
acyl
Prior art date
Application number
MX2021012743A
Other languages
English (en)
Inventor
Stephen Paul Collingwood
Stephen Allan Smith
Lisa Patel
Original Assignee
Modern Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modern Biosciences Ltd filed Critical Modern Biosciences Ltd
Publication of MX2021012743A publication Critical patent/MX2021012743A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere en general al campo de los compuestos terapéuticos. Más específicamente, la presente invención se refiere a determinados compuestos de N-acil-{4-[(4-aril-fenil)sulfonilmetil]piperidina} de la siguiente fórmula (denominados colectivamente en el presente documento compuestos de NASMP) que son útiles, por ejemplo, en el tratamiento de trastornos (por ejemplo, enfermedades) incluyendo, por ejemplo, mieloma múltiple, linfoma difuso de linfocitos B grandes, leucemia mieloide aguda, leucemia eosinófila, glioblastoma, melanoma, cáncer de ovario, cáncer resistente a la quimioterapia, cáncer resistente a la radiación, artritis inflamatoria, artritis reumatoide, artritis psoriásica, psoriasis, colitis ulcerosa, enfermedad de Crohn, lupus eritematoso sistémico (LES), nefritis por lupus, asma, enfermedad pulmonar obstructiva crónica (EPOC), hidradenitis supurativa, hepatitis autoinmunitaria, etc. La presente invención también se refiere a composiciones farmacéuticas que comprenden dichos compuestos, y al uso de dichos compuestos y composiciones, por ejemplo, en terapia. (ver Fórmula).
MX2021012743A 2019-04-18 2020-04-17 Compuestos de n-acil-{4-[(4-aril-fenil)sulfonilmetil]piperidina} y su uso terapeutico. MX2021012743A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1905520.1A GB201905520D0 (en) 2019-04-18 2019-04-18 Compounds and their therapeutic use
PCT/EP2020/060879 WO2020212581A1 (en) 2019-04-18 2020-04-17 N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use

Publications (1)

Publication Number Publication Date
MX2021012743A true MX2021012743A (es) 2021-11-17

Family

ID=66810170

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012743A MX2021012743A (es) 2019-04-18 2020-04-17 Compuestos de n-acil-{4-[(4-aril-fenil)sulfonilmetil]piperidina} y su uso terapeutico.

Country Status (16)

Country Link
US (1) US20230022917A1 (es)
EP (1) EP3956030A1 (es)
JP (1) JP2022528799A (es)
KR (1) KR20220002871A (es)
CN (1) CN113766953A (es)
AU (1) AU2020257561A1 (es)
BR (1) BR112021016672A2 (es)
CA (1) CA3132265C (es)
EA (1) EA202192032A1 (es)
GB (1) GB201905520D0 (es)
IL (1) IL287279A (es)
MA (1) MA55713A (es)
MX (1) MX2021012743A (es)
SG (1) SG11202109734SA (es)
WO (1) WO2020212581A1 (es)
ZA (1) ZA202106236B (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
BR0109353A (pt) * 2000-03-21 2003-04-08 Procter & Gamble Cadeia lateral heterocìclica contendo inibidores de metaloprotease
AU2002357312A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
JP2008545009A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
US20090069304A1 (en) 2006-03-03 2009-03-12 Shionogi & Co., Ltd. Mmp-13 selective inhibitor
CL2007003223A1 (es) 2006-11-10 2008-01-11 Wyeth Corp Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
EP2325182A1 (en) 2006-12-06 2011-05-25 Glaxosmithkline LLC Bicyclic compounds and use as antidiabetics
WO2009020140A1 (ja) 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. アダマンチルウレア誘導体
ES2428326T3 (es) 2007-10-04 2013-11-07 Merck Sharp & Dohme Corp. Derivados de aril sulfona sustituida como bloqueadores de canales de calcio
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
PL2858986T3 (pl) 2012-06-12 2020-03-31 Chong Kun Dang Pharmaceutical Corp. Pochodne piperydyny jako agoniści GPR119
US9693997B2 (en) 2013-03-06 2017-07-04 Hoffmann-La Roche Inc. Antiviral compounds
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
JP6650942B2 (ja) 2014-12-17 2020-02-19 ピムコ ２６６４ リミテッド Ｎ−（４−ヒドロキシ−４−メチル−シクロへキシル）−４−フェニル−ベンゼンスルホンアミド化合物、及びｎ−（４−ヒドロキシ−４−メチル−シクロへキシル）−４−（２−ピリジル）−ベンゼンスルホンアミド化合物、ならびにこれらの治療上の使用
CN111393414B (zh) 2015-01-22 2024-05-07 迈奥卡迪亚公司 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物

Also Published As

Publication number Publication date
US20230022917A1 (en) 2023-01-26
BR112021016672A2 (pt) 2021-10-13
GB201905520D0 (en) 2019-06-05
CA3132265C (en) 2023-12-19
CN113766953A (zh) 2021-12-07
EP3956030A1 (en) 2022-02-23
EA202192032A1 (ru) 2022-03-10
WO2020212581A1 (en) 2020-10-22
IL287279A (en) 2021-12-01
MA55713A (fr) 2022-02-23
AU2020257561A1 (en) 2021-10-28
ZA202106236B (en) 2023-05-31
JP2022528799A (ja) 2022-06-15
CA3132265A1 (en) 2020-10-22
SG11202109734SA (en) 2021-10-28
KR20220002871A (ko) 2022-01-07

Similar Documents

Publication Publication Date Title
Kamal et al. Quinazolinone linked pyrrolo [2, 1-c][1, 4] benzodiazepine (PBD) conjugates: Design, synthesis and biological evaluation as potential anticancer agents
PH12018500533A1 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
NI200500118A (es) Derivados de 3-(3,5-dioxo-4,5-dihidro-3h-(1,2,4) triazin-2-il)-benzamida como inhibidores de p2x7 para el tratamiento de enfermedades inflamatorias.
IN2012CH01573A (es)
NZ742476A (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
JOP20200342A1 (ar) مشتقات بيرازين مدمجة كمثبطات a2a/a2b
MX2011011048A (es) Nuevos agentes anti-inflamatorios.
NZ732126A (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
MY174788A (en) Bipyrazole derivatives as jak inhibitors
EA201492250A1 (ru) Гетероциклическое соединение
MX2014003042A (es) Nuevos derivados heterociclicos y sus usos.
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
MY173282A (en) Anti-baff-anti-il-17 bispecific antibodies
ZA202109179B (en) Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts
MX2017015370A (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
MX2017005281A (es) Etil n-boc piperidinil pirazolo piridonas como inhibidores de janus quinasa.
CY1119438T1 (el) Ν-(4-υδροξυ-4-μεθυλ-κυκλοεξυλ)-4-φαινυλ-βενζολοσουλφοναμιδια και ν-(4-υδροξυ-4-μεθυλ-κυκλοεξυλ)-4-(2-πυριδυλ)βενζολοσουλφοναμιδια και η θεραπευτικη τους χρηση
MX2017002775A (es) Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
GEP20227442B (en) Boron containing pde4 inhibitors
PH12020551494A1 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
WO2016100349A3 (en) Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2020002958A (es) Compuestos de porfirina sustituidos con fluoro, composiciones farmaceuticas que comprenden los mismos y metodos de preparacion y uso de los mismos.
MX2022015234A (es) Isoxazolidinas como inhibidores de ripk1 y uso de las mismas.